文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

季节性流感疫苗接种的真实世界有效性及年龄作为效应修饰因素:检测阴性设计研究的系统综述、Meta分析与Meta回归

Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
PubMed 文献 · Vaccine · 2024-02-28

该研究系统检索2017年1月1日至2022年12月31日发表的检测阴性设计研究,纳入191篇进行Meta分析。任何流感的总疫苗有效性(IVE)为41.4%(95%CI:39.2-43.5%),A/H3N2株的IVE显著低于A/H1N1和B/Yamagata株;IVE随年龄增长而降低,儿童高于成人及老年人。结论认为流感疫苗提供中等保护,但有效性因病毒型和年龄组而异,建议针对老年人和A/H3N2株调整接种策略并每年分析疫苗有效性。

要点

  • 任何流感的总IVE为41.4%(95%CI:39.2-43.5%)。
  • A/H3N2株IVE为26.8%,显著低于A/H1N1的55.4%和B/Yamagata的47.2%。
  • IVE在<18岁儿童为48.6%,18-64岁成人为36.7%,≥65岁老年人为30.6%。

核心结论

  • 流感疫苗对实验室确诊流感及相关门诊就诊和住院提供中等保护,但有效性可能因病毒型和年龄组而存在实质性差异。
  • 作者认为有必要针对老年人和A/H3N2株调整疫苗接种策略,并促进年度免疫和年度疫苗有效性分析。

研究设计与样本

  • 系统综述、Meta分析与Meta回归,检索2017年1月1日至2022年12月31日发表的检测阴性设计研究。
  • 共识别2429篇文献,最终纳入191篇进行Meta分析。

主要发现

  • 任何流感的总IVE为41.4%(95%CI:39.2-43.5%)。
  • A/H1N1的IVE为55.4%(95%CI:52.7-58.1%),A/H3N2为26.8%(95%CI:23.5-29.9%),B/Yamagata为47.2%(95%CI:38.1-54.9%),B/Victoria为40.6%(95%CI:23.7-53.7%)。
  • A/H3N2的IVE显著低于A/H1N1(p<0.0001)和B/Yamagata(p<0.0001)。
  • 预防流感相关门诊就诊的IVE为39.2%(95%CI:36.5-41.9%),预防流感相关住院的IVE为43.7%(95%CI:39.7-47.4%)。
  • 任何流感的IVE在<18岁儿童为48.6%(95%CI:44.7-52.2%),18-64岁成人为36.7%(95%CI:31.9-41.1%),≥65岁老年人为30.6%(95%CI:26.2-34.8%)。

关键数值与推荐

  • Meta回归显示IVE与研究参与者平均年龄相关:与儿童相比,年轻成人相对比值比(ROR)=1.225(95%CI:1.099-1.365,p=0.0002),老年人ROR=1.245(95%CI:1.083-1.431,p=0.002),均表现为有效性显著降低。

临床怎么用

  • 作者认为应针对老年人和A/H3N2株调整疫苗接种策略。
  • 作者认为应促进年度免疫和年度疫苗有效性分析。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Under the global risk of epidemic rebound of influenza after COVID-19 outbreak, the study aimed to provide a comprehensive evaluation of the seasonal influenza vaccine effectiveness (IVE) and to explore the potential effect modifiers. METHODS: We searched for test-negative design studies with IVE estimates published between January 1, 2017 and December 31, 2022. We estimated pooled IVE using random-effects meta-analysis, and conducted meta-regression with study site, age, sex and comorbidity as explanatory variables. RESULTS: We identified 2429 publications and included 191 in the meta-analysis. The pooled IVE was 41.4 % (95 % CI: 39.2-43.5 %) against any influenza. For specific strains, the IVE was 55.4 % (95 % CI: 52.7-58.1 %) against A/H1N1, 26.8 % (95 % CI: 23.5-29.9 %) against A/H3N2, 47.2 % (95 % CI: 38.1-54.9 %) against B/Yamagata, and 40.6 % (95 % CI: 23.7-53.7 %) against B/Victoria, and the effectiveness against A/H3N2 was significantly lower than A/H1N1 (p < 0.0001) and B/Yamagata (p < 0.0001). The pooled IVE was 39.2 % (95 % CI: 36.5-41.9 %) in preventing influenza-associated outpatient visit and 43.7 % (95 % CI: 39.7-47.4 %) in preventing influenza-related hospitalization. The IVE against any influenza was 48.6 % (95 % CI: 44.7-52.2 %) for children aged < 18 years, 36.7 % (95 % CI: 31.9-41.1 %) for adults aged 18-64 years, and 30.6 % (95 % CI: 26.2-34.8 %) for elderly aged ≥65 years. Meta-regression revealed that the IVE was associated with the average age of study participants, in which both young adults [relative odds ratio (ROR) = 1.225, 95 % confidence interval (CI): 1.099-1.365, p = 0.0002] and elderly (ROR = 1.245, 95 % CI: 1.083-1.431, p = 0.002) manifested a significantly decreased effectiveness compared with children. CONCLUSIONS: Influenza vaccines provided moderate protection against laboratory-confirmed influenza and related outpatient visit and hospitalization. However, the effectiveness may vary substantially by virus type and age group, suggesting the necessity to tailor vaccination strategies especially for older individuals and against the A/H3N2 strain, and to promote annual immunization and annual analysis of vaccine effectiveness.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Guo J, Chen X, Guo Y, et al. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine. 2024. PMID: 38423813. doi:10.1016/j.vaccine.2024.02.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。